142 related articles for article (PubMed ID: 10549730)
41. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.
Agnelli G; Sonaglia F
Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128
[TBL] [Abstract][Full Text] [Related]
42. Low molecular weight heparins: differences and similarities in approved preparations in the United States.
Bick RL; Fareed J
Clin Appl Thromb Hemost; 1999 Oct; 5 Suppl 1():S63-6. PubMed ID: 10726038
[TBL] [Abstract][Full Text] [Related]
43. Antithrombotic drugs in vascular medicine: a historical perspective.
Schrör K
Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
[TBL] [Abstract][Full Text] [Related]
44. The role of low-molecular-weight heparins in the management of unstable angina and non-ST elevation myocardial infarction.
Alwi I
Acta Med Indones; 2008 Oct; 40(4):228-32. PubMed ID: 19530369
[TBL] [Abstract][Full Text] [Related]
45. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism.
Martínez-González J; Vila L; Rodríguez C
Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):793-802. PubMed ID: 18570617
[TBL] [Abstract][Full Text] [Related]
46. Low-molecular-weight heparins for the treatment of acute coronary syndromes.
Wong GC; Giugliano RP
Semin Vasc Med; 2003 Nov; 3(4):391-402. PubMed ID: 15199446
[TBL] [Abstract][Full Text] [Related]
47. Antithrombotics and anticoagulants in coronary syndromes and stroke.
Turpie AG
Semin Thromb Hemost; 2000; 26 Suppl 1():79-83. PubMed ID: 11011811
[TBL] [Abstract][Full Text] [Related]
48. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
49. The use of antithrombotic drugs in older people.
Tufano A; Cerbone AM; Di Minno G
Minerva Med; 2002 Feb; 93(1):13-26. PubMed ID: 11850611
[TBL] [Abstract][Full Text] [Related]
50. Low-molecular-weight heparin in oncology.
Zacharski LR; Loynes JT
Anticancer Res; 2003; 23(3C):2789-93. PubMed ID: 12926114
[TBL] [Abstract][Full Text] [Related]
51. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
Nishioka J; Goodin S
J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
[TBL] [Abstract][Full Text] [Related]
52. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.
Mismetti P; Laporte S; Darmon JY; Buchmüller A; Decousus H
Br J Surg; 2001 Jul; 88(7):913-30. PubMed ID: 11442521
[TBL] [Abstract][Full Text] [Related]
53. [How to standardize low molecular weight heparins].
Doutremepuich C; Puyal C; Lalanne MC; Doutremepuich F; De Sèze O
Ann Biol Clin (Paris); 1990; 48(4):221-5. PubMed ID: 2163227
[TBL] [Abstract][Full Text] [Related]
54. [Low molecular weight heparins].
Doutremepuich C; Lalanne MC; Guyot M; Doutremepuich F; Fernandez G; De Seze O; Deharo E; Vairel EG; Quilichini R
Ann Pharm Fr; 1989; 47(3):109-16. PubMed ID: 2561387
[TBL] [Abstract][Full Text] [Related]
55. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
Walenga JM; Jackson CM; Kessler CM
Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
[TBL] [Abstract][Full Text] [Related]
56. Low-molecular-weight heparins: pharmacologic profile and product differentiation.
Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
Am J Cardiol; 1998 Sep; 82(5B):3L-10L. PubMed ID: 9737473
[TBL] [Abstract][Full Text] [Related]
57. Low-molecular-weight heparin.
Wolf H
Med Clin North Am; 1994 May; 78(3):733-43. PubMed ID: 8170267
[TBL] [Abstract][Full Text] [Related]
58. US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins.
Cohen M; Jeske WP; Nicolau JC; Montalescot G; Fareed J
J Thromb Thrombolysis; 2012 Apr; 33(3):230-8. PubMed ID: 22234748
[TBL] [Abstract][Full Text] [Related]
59. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins.
Fareed J; Walenga JM; Racanelli A; Hoppensteadt D; Huan X; Messmore HL
Haemostasis; 1988; 18 Suppl 3():33-47. PubMed ID: 2840373
[TBL] [Abstract][Full Text] [Related]
60. Low molecular weight heparins. An objective overview.
Hoppensteadt D; Walenga JM; Fareed J
Drugs Aging; 1992; 2(5):406-22. PubMed ID: 1327312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
